COVID COPY Flashcards
Nirmatrelvir- Ritonavir
MOA:
AE:
Efficacy:
MOA: inhibits viral protease enzyme (Mpro) = prevent viral replication
AE:
- Dose must be decreased for patients w/ renal dysfunction
- CYP 3A4 inhibitors = potential for serous drug interactions
-Efficacy: High
Remdesivir
MOA:
AE:
Efficacy
MOA: Inhibits viral RNA polymerase = disrupt viral replication
(active metabolite incorporated into viral RNA)
AE: IV for 3 days
Efficacy: Strong
First FDA approved Covid drug
Prodrug, converted into ATP analog inside cells (nucleotide analog)
Molnupiravir
MOA:
AE:
Efficacy:
MOA: Competes w/ cytidine triphosphate for incorporation into viral RNA –> creates extensive mutations in viral RNA
AE: Bone/ cartilage toxicity = not recommended for : children under 18, Pregnant ppl/ Anyone of childbearing potential
Efficacy: Not significant
Prodrug: nucleoside analog
Sotromivab
MOA:
AE:
Efficacy:
Monoclonal Antibody
MOA: mAb binding to virus blocks fusion & prevents viral entry into host cell (binds spike proteins)
AE: low availability, IV
Efficacy: High, effective against omicron, preferred option for symptomatic outpatients w/ severe risk of disease
MOA: inhibits viral protease enzyme (Mpro) = prevent viral replication
AE:
- Dose must be decreased for patients w/ renal dysfunction
- CYP 3A4 inhibitors = potential for serous drug interactions
-Efficacy: High
Nirmatrelvir- Ritonavir
MOA:
AE:
Efficacy:
MOA: Inhibits viral RNA polymerase = disrupt viral replication
(active metabolite incorporated into viral RNA)
AE: IV for 3 days
Efficacy: Strong
First FDA approved Covid drug
Prodrug, converted into ATP analog inside cells (nucleotide analog)
Remdesivir
MOA:
AE:
Efficacy
MOA: Competes w/ cytidine triphosphate for incorporation into viral RNA –> creates extensive mutations in viral RNA
AE: Bone/ cartilage toxicity = not recommended for : children under 18, Pregnant ppl/ Anyone of childbearing potential
Efficacy: Not significant
Prodrug: nucleoside analog
Molnupiravir
MOA:
AE:
Efficacy:
Monoclonal Antibody
MOA: mAb binding to virus blocks fusion & prevents viral entry into host cell (binds spike proteins)
AE: low availability, IV
Efficacy: High, effective against omicron, preferred option for symptomatic outpatients w/ severe risk of disease
Sotromivab
MOA:
AE:
Efficacy: